Protein C News and Research

RSS

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

1 Jun 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors.

1 Jun 2015

Secret to the life-long activity of a stem cell niche

The roots of a plant are constantly growing, so that they can provide the plant with water and minerals while also giving it a firm anchor in the ground. Responsible for these functions are pluripotent stem cells. In order to avoid differentiation and to remain pluripotent, these stem cells are dependent on signals from their neighbouring cells.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Caris Life Sciences® today announced the presentation of data from two studies in which researchers utilized Caris Molecular Intelligence®, the company's panomic, comprehensive tumor profiling service, to identify potential therapeutic targets in patients with colorectal and pancreatic cancer subtypes, based on expression of the programmed cell death protein 1 (PD-1) and its ligand, PD-L1.

1 Jun 2015

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

The Lancet Diabetes & Endocrinology is pleased to announce that the following paper will be published to coincide with presentation at the 52nd ERA-EDTA Congress, taking place in London, UK, May 28 - 31, 2015.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

The rapidly emerging field of precision medicine is a "disruptive innovation" that offers the possibility of remarkably fine-tuned remedies to improve patient health while minimizing the risk of harmful side effects, says J. Larry Jameson, MD, PhD, dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania for the Health System, in this week's issue of the New England Journal of Medicine.

1 Jun 2015

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

An intervention known as remote ischemic preconditioning (RIPC) significantly reduced the occurrence of acute kidney injury (AKI) in cardiac surgery patients and confirmed that post-operative elevations of two kidney biomarkers act as an alarm for risk of AKI, according to a study published online today in the Journal of the American Medical Association.

30 May 2015

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.

30 May 2015

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.

30 May 2015

Presence of collagen in tumor microenvironment can be either good or bad

The presence of collagen in the tumor microenvironment, essentially where the tumor lives, can be either good or bad according to Constance Brinckerhoff, PhD who led the Dartmouth team's reporting of "The BRAFV600E inhibitor, PLX4032, increases type 1 collagen synthesis in melanoma cells," in Matrix Biology Journal.

30 May 2015

Researchers discover new source for cells that can develop into coronary vessels

The heart has its own dedicated blood supply, with coronary arteries that supply oxygen-rich blood to the heart and cardiac veins that remove deoxygenated blood. This system of vessels nourishes the heart, enabling it to pump blood to all the other organs and tissues of the body. Yet despite their critical importance, the process and molecules required for coronary vessel development have not been fully determined.

30 May 2015

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

While squamous cell anal carcinomas are rare, representing only about 2% of digestive-system cancer diagnoses, these cancers, which are associated with the human papillomavirus (HPV), sometimes prove very difficult to treat, recurring or developing metastases following standard treatment.

30 May 2015

Canadian government improves access to gluten-free diets to mark Celiac Awareness Month

To mark Celiac Awareness Month, the Honourable Rona Ambrose, Minister of Health today announced changes that will result in more safe food choices for Canadians with celiac disease by approving "gluten-free" claims on specially produced oats and foods containing these oats.

30 May 2015

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20

30 May 2015

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

The world's leading organization of oncologists will honor Jim Allison, Ph.D., for his pioneering research that led to a new way to treat cancer by unleashing an immune system attack rather than targeting tumors directly.

30 May 2015

FVCG portfolio companies selected to present research at Bio International 2015

Actinobac Biomed, NovoPedics, Inc. and MentiNova, Inc., three biotech start-up companies originally funded with investments from Foundation Venture Capital Group (FVCG), have been selected to present their research at Bio International 2015 as part of the Start-Up Stadium and Company Presentation forums offered at the Conference, announced FVCG President James M. Golubieski.

30 May 2015

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

In the German Center for Infection Research (DZIF), scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: A highly effective protein from bacteria-specific viruses, so-called bacteriophages, shall rapidly kill the bacteria, which frequently occur in the nose.

30 May 2015

Main culprit of Alzheimer's disease causes memory loss

The study, published May 29 in the open access Nature Publishing Group journal Scientific Reports, reveals a direct link between the main culprit of Alzheimer's disease and memory loss.

29 May 2015

Protein C News and Research

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Secret to the life-long activity of a stem cell niche

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

Presence of collagen in tumor microenvironment can be either good or bad

Researchers discover new source for cells that can develop into coronary vessels

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

Canadian government improves access to gluten-free diets to mark Celiac Awareness Month

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

FVCG portfolio companies selected to present research at Bio International 2015

Scientists study active substance against dreaded hospital pathogen Staphylococcus aureus

Main culprit of Alzheimer's disease causes memory loss

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News